<DOC>
	<DOCNO>NCT00571298</DOCNO>
	<brief_summary>RATIONALE : After removal visible cancer chest , chemotherapy drug use kill stop tumor cell divide , stop grow or/and die . Cisplatin currently use safely intra-operative treatment malignant pleural mesothelioma . This study aim determine addition gemcitabine second intracavitary chemotherapy accomplish safely . PURPOSE : This Phase I trial study efficacy combination chemotherapy consist gemcitabine cisplatin administer operating room put chest abdomen one hour . We also look effect heat chemotherapy temperature 42 degree Celsius effect cytoprotection agent : amifostine sodium thiosulfate counteract potential side effect chemotherapy .</brief_summary>
	<brief_title>Extrapleural Pneumonectomy /Pleurectomy Decortication , IHOC Cisplatin Gemcitabine With Amifostine Sodium Thiosulfate Cytoprotection Resectable Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>- This dose escalation study gemcitabine fix dose cisplatin - Patients undergo cytoreductive surgery , entail removal inner outer line lung ( pleurectomy/decortication ) without lung ( extrapleural pneumonectomy ) , include line overlie pericardium diaphragm . Resection pericardium diaphragm occasionally necessary remove visable tumor . This surgery part standard care malignant pleural mesothelioma . - After surgery , one hour lavage heat cisplatin gemcitabine administer hemithorax ( abdominal region diaphragm longer present ) . - Patients remain hospitalized recover surgery ( usually 7-14 day ) . - Patients return hospital first month surgery evaluate medical staff . - Dose escalation : 1 ) Three patient treat first dose level gemcitabine . Labs monitor weekly basis , include CBC , Chem-7 , LFT 's . In absence develop dose-limiting toxicity ( DLT ) among first 3 patient treat , dosage escalate . DLT define grade 3 high renal toxicity , thrombocytopenia grade 3 toxicity relate surgery 2 ) If none 3 patient toxicity , proceed next level gemcitabine . 3 ) If DLT occur 1 3 patient give dose level , 3 additional patient add dose ( total 6 level ) If DLT occur , proceed next level gemcitabine . If DLT occur another patient , dose consider maximum tolerate dose ( MTD ) . 4 ) At dose , 3 case DLT lead discontinuation recruitment dose enrollment 3 additional patient low dose .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Histologicallyproven diagnosis stage I III malignant mesothelioma pleura negative mediastinal N2 lymph node ( Malignancy confine affected hemithorax ) Adequate organ function include follow : adequate cardiac function , pulmonary function , renal hepatic function bone marrow reserve Adequate overall physical activity Surgical candidate cytoreductive surgery Extended disease outside ipsilateral hemithorax proven histologically , radiologically and/or intraoperatively Have receive chemotherapy radiation therapy within last 3 year time study entry Serious concomitant systemic disorder Second active primary malignancy ( exclude non melanoma skin cancer ) Pregnancy time operation Psychiatric addictive disorder would preclude obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Extrapleural pneumonectomy</keyword>
	<keyword>Pleurectomy Decortication</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>amifostine</keyword>
	<keyword>sodium thiosulfate</keyword>
</DOC>